Trademark Overview
On Thursday, August 28, 2025, a trademark application was filed for NAVSYRNA with the United States Patent and Trademark Office. The USPTO has given the NAVSYRNA trademark a serial number of 99363013. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, August 28, 2025. This trademark is owned by Amgen Inc.. The NAVSYRNA trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
